Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

AstraZeneca, Definiens Deal Builds Cancer Immunotherapy Capability

November 4, 2014 10:05 am | News | Comments

AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has pioneered a world-leading imaging and data analysis technology, known as Tissue Phenomics™, which dramatically improves the identification of biomarkers in tumor tissue. Read more...

TOPICS:

Scientists Try to Predict Number of U.S. Ebola Cases

November 3, 2014 3:04 pm | by Martha Mendoza – AP National Writer – Associated Press | News | Comments

Top medical experts studying the spread of Ebola say the public should expect more cases to emerge in the United States by year's end as infected people arrive here from West Africa, including American doctors and nurses returning from the hot zone and people fleeing from the deadly disease. Read more... 

TOPICS:

Are My Muscular Dystrophy Drugs Working?

November 3, 2014 1:31 pm | News | Comments

People with muscular dystrophy could one day assess the effectiveness of their medication with the help of a smartphone-linked device, a new study in mice suggests.  Read more...                       

TOPICS:
Advertisement

BDSI's Opioid Dependence Treatment Now Available in U.S.

November 3, 2014 1:23 pm | News | Comments

BioDelivery Sciences International, Inc.announced that Bunavail (buprenorphine and naloxone) buccal film (CIII) is now commercially available. Read more...                                               

TOPICS:

Actavis, Durata Therapeutics Get FTC Clearance

November 3, 2014 1:08 pm | News | Comments

Actavis plc and Durata Therapeutics, Inc. announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to Actavis' pending acquisition of Durata. Read more...

TOPICS:

Biosimilar Medications Could Create Billions in Savings

November 3, 2014 12:59 pm | News | Comments

Introducing competing “biosimilar” versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation. Read more...

TOPICS:

Nasal Spray Vaccine Could Protect Against Ebola Virus

November 3, 2014 12:44 pm | News | Comments

A nasal vaccine in development by researchers at The University of Texas at Austin has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Read more...

TOPICS:

Researcher Debunks Alzheimer's Development Theory

November 3, 2014 12:36 pm | News | Comments

New research points to tau, not amyloid-beta (Abeta) plaque, as the seminal event that spurs neuron death in disorders such as Alzheimer's disease. The finding, which dramatically alters the prevailing theory of Alzheimer's development, also explains why some people with plaque build-up in their brains don't have dementia. Read more...

TOPICS:
Advertisement

Inventiva Gains Positive Opinion for Orphan Drug Designation

November 3, 2014 11:20 am | News | Comments

Inventiva has received a positive opinion for a new orphan drug designation for systemic sclerosis. Read more...                         

TOPICS:

Pharming, Salix Launch HAE Treatment

November 3, 2014 11:16 am | News | Comments

Pharming Group NV and Salix Pharmaceuticals, Ltd. announced the launch of Ruconest (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg in the United States for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Read more...

TOPICS:

Regulatory Data: Vital for DDI Risk-Mitigation Efforts

November 3, 2014 11:04 am | by Philip MacLaughlin, Product Director, PharmaPendium, Elsevier | Articles | Comments

Unanticipated adverse drug-drug interactions (DDIs) have led to the withdrawal of several high-profile drugs that had been available for a number of years, including terfenadine, astemizole, cisapride, grepafloxacin and mibefradil.  Read more... 

TOPICS:

BMS Signs Exclusive Option for New Pulmonary Fibrosis Inhibitor

November 3, 2014 10:52 am | News | Comments

Bristol-Meyers Squibb and Galecto Biotech AB announced that the companies have entered into an agreement that provides BMS the exclusive option to acquire a a novel inhaled inhibitor for the treatment of idiopathic pulmonary fibrosis. Read more...  

TOPICS:

Gates Foundation Boosts Aid to Stamp Out Malaria

November 3, 2014 9:11 am | by Marilynn Marchione - AP Chief Medical Writer | News | Comments

Philanthropist Bill Gates says he wants to end malaria in his lifetime and will give more money toward that goal. Read more...                       

TOPICS:

The Man with a Thousand Brains

November 3, 2014 8:56 am | News | Comments

Forty million people worldwide are living with Alzheimer’s and this is only set to increase. But tiny brains grown in culture could help scientists learn more about this mysterious disease – and test new drugs. Read more...                          

TOPICS:

First Human Clinical Trial of 'C dots' Highlights Safety

October 31, 2014 2:14 pm | News | Comments

A first clinical trial of these ultrasmall, multifunctional particles has deemed them safe for humans and cleared easily by the body. Read more...                   

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading